Skip to main content

Advertisement

Table 2 Subanalysis of treatment efficacy in patients treated with MMF

From: Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study

  ARR p EDSS P On-MMF, Patients, %
Median (Range) Median (Range) Relapse free Improved ARR Improved or Stabilized EDSS
Total patients (n = 86)
 Pre-MMF treatment 1.4(0.1–11) < 0.0001 3(0–8.5) 0.006 64 87 87
 on-MMF treatment 0(0–2.8) 2.5(0–8.5)
Patients with high dose MMF treatment (n = 52)
 Pre-MMF treatment 1.5(0.1–11) < 0.0001 3(0–8.5) 0.511 81 92 89
 on-MMF treatment 0(0–2.8) 2.5(0–8.5)
Patients with moderate dose MMF treatment (n = 23)
 Pre-MMF treatment 1.4(0.2–6) 0.0003 3(0–8.5) 0.071 52 78 83
 on-MMF treatment 0(0–2.2) 2(0–6.5)
Patients with low dose MMF treatment (n = 11)
 Pre-MMF treatment 1.2(0.5–6) 0.0078 4(0–8.5) 0.438 9 82 91
 on-MMF treatment 0.5(0–1.0) 4(0–8.5)
  1. pre-MMF before initiation of MMF treatment, on-MMF during treatment of MMF